NEWS: September 2023

The GTC are delighted that we have been able to license our novel lentivirus platform technology to AlveoGene, a new tripartite University spin-out company, with financing provided by Oxford Science Enterprises (UK), Harrington Discovery (US) and Old College Capital (UK). This partnership will catalyse the translation of new genetic therapies for a number of rare respiratory diseases, with a first target being alpha1-antitrypsin deficiency. Details are provided in the press release which can be found at www.alveogene.com. The use of our platform technology to deliver the CFTR gene (relevant to cystic fibrosis), has already been partnered with Boehringer Ingelheim and is, therefore, not part of this new venture.

​

Eric Alton, on behalf of the UK Respiratory Gene Therapy Consortium

​

​